Studies have shown that high expression of SLC31A1 is negatively associated with sensitivity to several breast cancer chemotherapy protocols, including CEF (cyclophosphamide, epirubicin, and fluorouracil) plus docetaxel or paclitaxel and AT (anthracycline, taxane) [27]; however, another study has shown that high expression of SLC31A1 in breast cancer predicts that patients are more sensitive to paclitaxel regimens‐alone [12]. Here, SLC31A1 is linked to breast carcinoma.